Table 1 Baseline characteristics of the studied cases
Transition of AKI to CKD | p-value | ||
|---|---|---|---|
Negative (n = 201) | Positive (n = 51) | ||
Age/years | 56.26 ± 17.7 | 63.84 ± 13.9 | = 0.005* |
Sex | |||
• Female | 84 (41.8%) | 13 (25.5%) | = 0.033** |
• Male | 117 (58.2%) | 38 (74.5%) | |
Comorbidity | |||
• DM | 85 (42.3%) | 26 (51%) | = 0.264** |
• HTN | 75 (37.3%) | 25 (49%) | = 0.127** |
• Cardiac | 49 (24.4%) | 29 (56.9%) | = 0.001** |
• Hepatic | 49 (24.4%) | 6 (11.8%) | = 0.051** |
• Chest | 17 (8.5%) | 6 (11.8%) | = 0.464** |
• Hematology | 5 (2.5%) | 3 (5.9%) | = 0.217*** |
• Malignancy | 29 (14.4%) | 7 (13.7%) | = 0.898** |
• Endocrine | 10 (5%) | 3 (5.9%) | = 0.749*** |
• CVS | 20 (10%) | 11 (21.6%) | = 0.024** |
• Autoimmune | 14 (7%) | 1 (2%) | = 0.317*** |
LHS/days | 9.25 ± 1.5 | 10.29 ± 1.9 | = 0.331* |
Risk factor | |||
• Bleeding | 33 (16.4%) | 11 (21.6%) | = 0.387** |
• Dehydration | 65 (32.3%) | 12 (23.5%) | = 0.223** |
• Shock | 69 (34.3%) | 14 (27.5%) | = 0.351** |
• Infection | 157 (78.1%) | 44 (86.3%) | = 0.195** |
• Drugs | 16 (8%) | 8 (15.7%) | = 0.093** |
• Contrast | 6 (1.5%) | 3 (5.9%) | = 0.319*** |
• Obstruction | 3 (1.5%) | 4 (7.8%) | = 0.014** |
• GN | 2 (1%) | 1 (2%) | = 0.494*** |
• Others | 22 (10.9%) | 4 (7.8%) | = 0.515** |